Uncommon EGFR Mutations Research Overview At MOASC Spotlight 2025, Dr. Darren Wijaya, MD, from Loma Linda University Health, shared vital…
Browsing: progression-free survival
The Camizestrant SERENA-6 trial shone at ASCO 2025, presented by Professor Nick Turner. This Phase 3 study targets ESR1-mutated, ER-positive,…
At the 2025 ASCO Annual Meeting, a phase 3 randomized trial revealed that the timing of immunotherapy in non-small cell…
Katy Beckermann, MD, PhD – Vanderbilt University The phase 3 TiNivo-2 study (NCT04987203), sponsored by AVEO Pharmaceuticals, Inc., recently…